DCOY is trading at $7.00 (8.1% down) in pre-market, pulling back after sharp gains tied to recent financing news.

  • Decoy Therapeutics recently announced a private placement securing $3.5 million upfront and up to $21 million total to fund clinical trials for its respiratory viral illness programs.
  • The current move reflects ongoing market digestion of the highly dilutive funding deal following a major rally earlier this week.